Cryopyrin associated periodic syndromes

From WikiMD's Wellnesspedia

Other Names[edit | edit source]

CAPS; Cryopyrinopathy

Autosomal dominant pedigree

Clinical features[edit | edit source]

  • Cryopyrin-associated periodic syndrome (CAPS) is a rare hereditary inflammatory disorder.
  • Clinical features include cutaneous, neurological, ophthalmologic, and rheumatologic manifestations.

Signs and symptoms[edit | edit source]

Most common symptoms include fever, fatigue, malaise, mood disorders or failure to thrive, urticarial or maculopapular rash, myalgia, arthralgia, and/or arthritis, joint contracture, patellar overgrowth, bone deformity, bone erosion and/or osteolytic lesion, conjunctivitis and/or uveitis, optic nerve atrophy, cataract, glaucoma or impaired vision, neurosensory hearing loss, morning headache, papilloedema, and/or meningitis, seizure, hydrocephalus or mental retardation and amyloidosis.

Types[edit | edit source]

It has thee types:

  1. Familial cold autoinflammatory syndrome,
  2. Muckle-Wells syndrome, and
  3. Neonatal-onset multisystem inflammatory disease.

Cause[edit | edit source]

  • CAPS results from a gain-of-function mutation of the NLRP3 gene coding for cryopyrin, which forms intracellular protein complexes known as inflammasomes.
  • Defects of the inflammasomes lead to overproduction of interleukin-1, resulting in inflammatory symptoms seen in CAPS.

Inheritance[edit | edit source]

It is a genetic disease transmitted in an autosomal dominant manner.

Diagnosis[edit | edit source]

Diagnosis is often delayed and requires a thorough review of clinical symptoms.

Treatment[edit | edit source]

  • In February 2008, rilonacept (Arcalyst) was approved for treatment of cryopyrin-assisted periodic syndromes (CAPS).
  • In June 2009, canakinumab (Ilaris) was approved for the treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older.
  • Canakinumab is manufactured by Novartis Pharmaceuticals Corporation under brand name Ilaris.
  • In May 2013, Ilaris was also approved for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.

NIH genetic and rare disease info[edit source]

Cryopyrin associated periodic syndromes is a rare disease.


Cryopyrin associated periodic syndromes Resources

Find a healthcare provider anywhere in the world quickly and easily!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD